Preprint on effect in baboons:
https://www.biorxiv.org/content/10.64898/2026.02.12.705540v1.full
Western-style diets promote chronic metabolic inflammation and dyslipidemia, yet safe interventions that restore immunometabolic homeostasis remain limited. Pyrroloquinoline quinone (PQQ) is a naturally occurring redox cofactor with antioxidant and metabolic regulatory properties, but its systemic effects in translational preclinical models are poorly defined. Here, we examined the impact of short-term PQQ supplementation in obese adult female olive baboons (Papio anubis ) chronically fed a Western diet. Using a human-equivalent dose administered for 30 days, we found that PQQ supplementation significantly reduced circulating markers of systemic inflammation and cholesterol in Western-diet-fed animals, lowering circulating C-reactive protein, soluble CD163, and atherogenic lipoprotein fractions independent of changes in adiposity.
To get a decent amount of PQQ one probably should consume a lot of fruits and vegetables, as one won’t get a lot of it in meat. A high meat diet that is also low in fruit and vegetables is probably low in PQQ.
The Primate Reset: How a Bacterial Cofactor Silences the “Western Diet” Signal
Modern Western diets are essentially metabolic noise, triggering chronic inflammation and dyslipidemia that pave the way for obesity-related pathologies. While weight loss is the traditional gold standard for health restoration, new research suggests we might be able to “reprogram” the body’s response to poor nutrition without changing the scale. A study conducted by researchers at the University of Oklahoma Health Campus reveals that Pyrroloquinoline quinone (PQQ) —a naturally occurring redox cofactor found in foods like parsley, green peppers, and kiwi—can rapidly overhaul the systemic immunometabolic networks of primates.
The researchers studied obese female olive baboons, a highly translational model due to their genetic and physiological similarities to humans. These animals were chronically fed a high-fat, high-sugar Western diet. For 30 days, the baboons received a human-equivalent dose of PQQ (20 mg/day). The results were striking: despite no change in body weight or subcutaneous fat, the systemic inflammatory profile of the animals was significantly “cooled”.
Proteomic analysis of the blood revealed that PQQ didn’t just act as a simple antioxidant. It acted as a master regulator. It suppressed “thrombo-inflammatory” pathways and the complement system—the body’s ancient immune alarm system—while simultaneously enhancing the pathways responsible for assembling and clearing atherogenic cholesterol . Most importantly, the study identified two “pioneer” targets of PQQ: FOXA2 , a transcription factor that manages hepatic lipid metabolism, and NTRK1 , a receptor involved in nerve-to-fat communication . By activating these pathways, PQQ effectively reversed the metabolic damage of a Western diet at the molecular level, offering a potential “metabolic insurance policy” for those struggling with diet-induced stress.
Actionable Insights
-
Targeted Supplementation: The study utilized a human-equivalent dose of 20 mg/day (scaled to 0.25 mg/kg in primates). This dose is widely available in commercial PQQ supplements (e.g., BioPQQ).
-
Decoupling Weight from Health: PQQ improved inflammatory markers (CRP) and cholesterol levels (LDL/VLDL) independent of weight loss. This suggests PQQ is a tool for “metabolic health” even if fat loss remains stalled.
-
Inflammation Control: PQQ significantly reduced C-reactive protein (CRP) and soluble CD163 , a marker for macrophage activation. Those with high systemic inflammation may see rapid (30-day) benefits.
-
Pre-Pregnancy Optimization: The researchers suggest that improving metabolic health in overweight/obese women via PQQ prior to pregnancy could potentially improve fetal health by reducing the maternal “inflammatory load”.
-
Bioavailability Strategy: In the study, PQQ was delivered orally in a palatable treat. While not explicitly stated, consistency in daily intake was key to achieving the observed systemic reprogramming.
Context & Impact Evaluation
- Institution: University of Oklahoma Health Campus.
- Country: United States.
- Journal Name: bioRxiv (Preprint)
A summary of the initial paper: Effects of Pyrroloquinoline Quinone (PQQ) Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men
Mitochondrial Biogenesis vs. Aerobic Gains: The PQQ Paradox
For decades, the search for “exercise in a pill” has focused on compounds capable of mimicking or enhancing the cellular adaptations triggered by physical exertion. A primary target in this quest is peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1a) , the so-called “master regulator” of mitochondrial biogenesis. Pyrroloquinoline quinone (PQQ) , a vitamin-like redox cofactor found in plant-based foods, has recently emerged as a potent activator of this pathway in animal models. However, translating these rodent-based successes to human physiology has remained a significant knowledge gap.
A clinical trial conducted at Baylor University in the United States , published in the Journal of the American College of Nutrition , sought to bridge this gap by examining whether PQQ supplementation could amplify the benefits of a six-week endurance training program in untrained men. The study followed 23 participants randomized to receive either 20 mg of PQQ daily or a placebo while undergoing supervised cycling sessions five days per week.
The results present a fascinating molecular disconnect. On a cellular level, PQQ lived up to its reputation: the supplement group exhibited a significantly greater increase in PGC-1a protein levels within the vastus lateralis muscle compared to the placebo group. This strongly suggests that PQQ acts as a “spark plug” for mitochondrial biogenesis, signaling the body to build more cellular power plants.
Surprisingly, this molecular surge did not translate into superior physical performance. Both groups saw nearly identical improvements in VO2peak , exercise duration, and ventilatory threshold. Furthermore, despite early indicators of PQQ’s potential role in lipid metabolism, no significant differences were found in body composition or fat loss between the groups. The “Big Idea” here is that while PQQ clearly activates the signaling machinery for mitochondrial growth, six weeks is likely insufficient for these molecular changes to manifest as tangible aerobic advantages over exercise alone.
Actionable Insights
-
Targeted Biogenesis: Supplementing with 20 mg/day of PQQ in conjunction with endurance exercise significantly elevates PGC-1a protein levels. This suggests a potential for long-term mitochondrial health even if performance gains are not immediate.
-
The “Co-Factor” Requirement: PQQ should not be viewed as a standalone performance enhancer; improvements in aerobic capacity in this study were driven primarily by the exercise stimulus itself.
-
Patience for Body Composition: Despite a 17.61% larger (though statistically non-significant) reduction in fat mass in the PQQ group, the study confirms that PQQ is not a “magic bullet” for fat loss over a short six-week window.
-
Dosing and Purity: The study utilized 99% pure PQQ at a dose of 20 mg/day. Biohackers should ensure supplement purity matches clinical standards to replicate these signaling effects.
-
Molecular Priming: Clinicians may consider PQQ as a tool to “prime” the mitochondrial environment, particularly for those with impaired biogenesis pathways, though further data is needed on clinical populations.
Context and Impact Evaluation
- Institution: Baylor University, Exercise and Biochemical Nutrition Laboratory.
- Country: USA.
- Journal: Journal of the American College of Nutrition.
- Impact Evaluation: The impact score (CiteScore/JIF) of this journal is approximately 3.17, evaluated against a typical high-end range of 0–60+ for top general science; therefore, this is a Medium impact journal.